Ivabradina, insufficienza cardiaca e malattia renale cronica

Giovanni Barbera; Alberto Santoboni; Antonio De Pascalis; Rodolfo Rivera; Fulvio Floccari; Claudio Ronco; Luca Di Lullo

doi:10.33393/gcnd.2015.808

Authors

Giovanni Barbera U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)
Alberto Santoboni U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)
Antonio De Pascalis U.O.C. Nefrologia, Dialisi e Trapianto, Ospedale V. Fazzi, Lecce
Rodolfo Rivera U.O.C. Clinica Nefrologica, Ospedale S. Gerardo, Monza (MB)
Fulvio Floccari U.O.C. Nefrologia e Dialisi, Ospedale S. Paolo, Civitavecchia (RM)
Claudio Ronco International Renal Research Institute, Ospedale S. Bortolo, Vicenza
Luca Di Lullo U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)

DOI:

https://doi.org/10.33393/gcnd.2015.808

Keywords:

Heart failure, Comorbidities, Ivabradine, SHIFT trial, Morbidity, Mortality, Hospitalizations, Ventricular remodelling, Beta-blockers

Abstract

Ivabradine, heart failure and chronic kidney disease Incidence and prevalence of congestive heart failure are raising, especially in western countries. In Europe and in the United States it represents a disabling clinical disease for all injured people and it's accountable for the increase of hospitalization and sanitary costs. European guidelines have underlined the importance of the optimization of pharmacological treatment to improve both patients' outcomes and quality of life. SHIFT trial's results, based on the evaluation of ivabradine's efficacy if added to conventional congestive heart failure's therapy, seem to proceed in that direction. (Cardionephrology)